For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent protections expiring in 2028. The FDA has approved a subcutaneous version of ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely active ulcerative colitis. Perspective from David T. Rubin, MD The approval ...

Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and intravenous induction options in ulcerative colitis, providing flexibility and simplicity for patients ...

A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

The FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years or older. Recommended dosages are 395 mg/4800 U every 3 weeks or 790 mg/9600 U every 6 ...

"Historically, IL-23 inhibitors have required IV infusions at the start of therapy, which can create barriers to starting treatment or be burdensome for some patients and clinicians," said David T.

During a Wednesday broadcast of Fox and Friends, Kilmeade was having a discussion with co-hosts Lawrence Jones and Ainsley Earhardt about Zarutska, the 23-year-old Ukrainian woman was stabbed and ...

“I apologize for that extremely callous remark,” the ‘Fox and Friends’ host said during Sunday’s broadcast. By Lexy Perez Associate Editor Fox and Friends host Brian Kilmeade has issued an apology for ...